跳至主要内容
临床试验/NCT05526807
NCT05526807终止不适用

Feasibility Studies to Investigate the Role of Ursodeoxycholic Acid in the Prevention of Recurrence of C. Difficile Infection

Nottingham University Hospitals NHS Trust1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2019年5月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
6
试验地点
1
主要终点
To assess tolerability to oral ursodeoxycholic acid

研究概览

简要总结

The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Completion of a course of antibiotic treatment for C. difficile infection within the previous 7 days

排除标准

  • • Pregnant or Breast-feeding
  • Gall bladder inflammation
  • Frequent episodes of biliary colic
  • Occlusion of the common bile duct or cystic duct
  • Active small intestinal inflammation
  • Previous resection of distal small intestine
  • Treatment with bile salt binding agents, ciclosporin or ciprofloxacin
  • Diarrhoea (from any cause) at study initiation
  • hypersensitivity to bile acids or any excipient of the formulation
  • Life expectancy less than 6 months

研究组 & 干预措施

Ursodeoxycholic acid

Experimental

Only one arm - subjects receiving ursodeoxycholic acid

干预措施: Ursodeoxycholic acid (Drug)

结局指标

主要结局

To assess tolerability to oral ursodeoxycholic acid

时间窗: 6 weeks

Assess for side effects

次要结局

  • To determine recurrence of C. difficile infection in those able to take ursodeoxycholic acid(12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验